BioCentury
ARTICLE | Product Development

Radiopharmaceuticals’ multi-dimensional next wave

Target, ligand and radioisotope choices fuel the growing field

December 1, 2023 1:15 AM UTC

The resurgence of targeted radiopharmaceuticals has created an ecosystem of companies testing combinatorial hypotheses about how best to align target, ligand and radioisotope choices to treat different cancers. 

Ten years into its second wave, the field has seen four approvals and four $1B-plus acquisitions, and now has lines of sight to earlier treatment settings and blockbuster sales. ...